The distinctive nature of adenocarcinoma of the lung

References

• ZengCWenWMorgansAKPaoWShuXOZhengWDisparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010JAMA Oncol201511889626182310
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med20083581160117418337605
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer2005534135415864276
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJännePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
   PubMed Web of Science ®Google Scholar
• DungoRTKeatingGMAfatinib: first global approvalDrugs2013731503151523982599
   PubMed Web of Science ®Google Scholar
• LangerCJEpidermal growth factor receptor inhibition in mutationpositive non-small-cell lung cancer: is afatinib better or simply newer?J Clin Oncol2013313303330623980079
   PubMed Web of Science ®Google Scholar
• RielyGJPolitiKAMillerVAPaoWUpdate on epidermal growth factor receptor mutations in non-small cell lung cancerClin Cancer Res2006127232724117189394
   PubMed Web of Science ®Google Scholar
• HirschFRBunnPAJrEGFR testing in lung cancer is ready for prime timeLancet Oncol20091043243319410185
   PubMed Web of Science ®Google Scholar
• MitsudomiTYatabeYEpidermal growth factor receptor in relation to tumor development: EGFR gene and cancerFEBS J2010277230130819922469
   PubMed Web of Science ®Google Scholar
• GiacconeGRodriguezJAEGFR inhibitors: what have we learned from the treatment of lung cancer?Nat Clin Pract Oncol2005255456116270096
   PubMedGoogle Scholar
• CappuzzoFHirschFRRossiEEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerJ Natl Cancer Inst20059764365515870435
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med20052e1715696205
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol2013313327333423816960
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• CappuzzoFJännePASkokanMMET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnn Oncol200920229830418836087
   PubMed Web of Science ®Google Scholar
• YasudaHKobayashiSCostaDBEGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsLancet Oncol2012131e23e3110.1016/S1470-2045(11)70129-2 Epub 2011 Jul 19. Review21764376
   PubMed Web of Science ®Google Scholar
  ErratumLancet Oncol201112131182
   Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med2011375ra26
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med20052e7315737014
   PubMed Web of Science ®Google Scholar
• RosellRMolinaMACostaCPretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutationsClin Cancer Res2011171160116821233402
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• OxnardGRStrategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancerArch Pathol Lab Med20121361205120923020725
   PubMed Web of Science ®Google Scholar
• SudaKMizuuchiHMaeharaYMitsudomiTAcquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation – diversity, ductility, and destinyCancer Metastasis Rev20123180781422736441
   PubMed Web of Science ®Google Scholar
• OxnardGRArcilaMESimaCSAcquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationClin Cancer Res2011171616162221135146
   PubMed Web of Science ®Google Scholar
• SoriaJCWuYLNakagawaKGefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncol2015 pii: S1470-2045(15)00121-7
   Web of Science ®Google Scholar
• GainorJFShawATEmerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJ Clin Oncol2013313987399624101047
   PubMed Web of Science ®Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A20051027665767015897464
   PubMed Web of Science ®Google Scholar
• JännePABossDSCamidgeDRPhase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsClin Cancer Res20111751131113921220471
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
  ErratumLancet Oncol2012135e186
   Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
   PubMed Web of Science ®Google Scholar
• SequistLVSoriaJCGoldmanJWRociletinib in EGFR-mutated non-small-cell lung cancerN Engl J Med2015372181700170925923550
   PubMed Web of Science ®Google Scholar
• JännePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• ManoHNon-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancerCancer Sci2008992349235519032370
   PubMed Web of Science ®Google Scholar
• PalmerRHVernerssonEGrabbeCAnaplastic lymphoma kinase: signalling in development and diseaseBiochem J200942034536119459784
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• SasakiTRodigSJChirieacLRThe biology and treatment of EML4-ALK non-small cell lung cancerEur J Cancer2010461773178020418096
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancerClin Cancer Res2009153143314919383809
   PubMed Web of Science ®Google Scholar
• HernandezLPinyolMHernandezSTRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocationsBlood19999493265326810556217
   PubMed Web of Science ®Google Scholar
• GridelliCPetersSSgambatoACasaluceFAdjeiAACiardielloFALK inhibitors in the treatment of advanced NSCLCCancer Treat Rev201440230030623931927
   PubMed Web of Science ®Google Scholar
• GuptaRDastaneAMMcKennaRJrMarchevskyAMThe predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current ‘best evidence’ with meta-analysisHum Pathol20094035636518976796
   PubMed Web of Science ®Google Scholar
• CamidgeDRKonoSAFlaccoAOptimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for alk inhibitor treatmentClin Cancer Res2010165581559021062932
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol2009274247425319667264
   PubMed Web of Science ®Google Scholar
• TakahashiTSonobeMKobayashiMClinicopathologic features of non small-cell lung cancer with EML4-ALK fusion geneAnn Surg Oncol20101788989720183914
   PubMed Web of Science ®Google Scholar
• WongDWLeungELSoKKThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRASCancer20091151723173319170230
   PubMed Web of Science ®Google Scholar
• ZhangXZhangSYangXFusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMol Cancer2010918820624322
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med20103631693170320979469
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med20133682385239423724913
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• SørensenJBHansenHHHansenMBrain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosisJ Clin Oncol19886147414803047337
   PubMed Web of Science ®Google Scholar
• SasakiTOkudaKZhengWThe neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersCancer Res201070100381004321030459
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med20103631734173920979473
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged kung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in ALK gene rearranged non-small cell lung cancerClin Cancer Res2014181472148222235099
   PubMed Web of Science ®Google Scholar
• ShawATKimDWMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med20143701189119724670165
   PubMed Web of Science ®Google Scholar
• SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non small cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncol201314759059823639470
   PubMed Web of Science ®Google Scholar
• IragavarapuCMustafaMAkinleyeANovel ALK inhibitors in clinical use and developmentJ Hematol Oncol2015811725888090
   PubMed Web of Science ®Google Scholar
• PetrioliRFranciniEFiaschiAISwitch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II studyMed Oncol201532413425796503
   PubMed Web of Science ®Google Scholar
• SetoTKatoTNishioMErlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyLancet Oncol201415111236124425175099
   PubMed Web of Science ®Google Scholar
  ErratumLancet Oncol20141511e475
   Google Scholar
• DrilonAWangLHasanovicAResponse to cabozantinib in patients with RET fusion-positive lung adenocarcinomasCancer Discov2013363063523533264
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol20123086387022215748
   PubMed Web of Science ®Google Scholar
• OuSHTanJYenYSooRAROS1 as a ‘druggable’ receptor v tyrosine kinase: lessons learned from inhibiting the ALK pathwayExpert Rev Anticancer Ther20121244745622500682
   PubMed Web of Science ®Google Scholar
• TakeuchiKSodaMTogashiYRET, ROS1 and ALK fusions in lung cancerNat Med20121837838122327623
   PubMed Web of Science ®Google Scholar
• UliviPZoliWCapelliLChiadiniECalistriDAmadoriDTarget therapy in NSCLC patients: relevant clinical agents and tumour molecular characterisationMol Clin Oncol20131457558124649213
   PubMedGoogle Scholar
• GuPZhaoYZJiangLYZhangWXinYHanBHEndobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysisEur J Cancer2009451389139619124238
   PubMed Web of Science ®Google Scholar
• AnnemaJTVersteeghMIVeseliçMEndoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancerJAMA200529493193616118383
   PubMed Web of Science ®Google Scholar
• TournoyKGRintoulRCvan MeerbeeckJPEBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopyLung Cancer200963454918514365
   PubMed Web of Science ®Google Scholar
• ChenJTLaneMAClarkDPInhibitors of the polymerase chain reaction in Papanicolaou stain. Removal with a simple destaining procedureActa Cytol1996408738778842159
   PubMed Web of Science ®Google Scholar
• SmithGDChadwickBEWillmore-PayneCaBentzJSDetection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysisJ Clin Pathol20086148749317908804
   PubMed Web of Science ®Google Scholar
• SmouseJHCibasESJännePAJoshiVAZouKHLindemanNIEGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancerCancer2009117677219347832
   PubMed Web of Science ®Google Scholar
• SavicSTapiaCGrilliBComprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancersBr J Cancer20089815416018087280
   PubMed Web of Science ®Google Scholar
• UliviPRomagnoliMChiadiniEAssessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patientsInt J Oncol20124114715222504767
   PubMed Web of Science ®Google Scholar
• UliviPZoliWChiadiniEEGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patientsEur Respir J20124026726922753836
   PubMed Web of Science ®Google Scholar
• KimuraHKasaharaKKawaishiMDetection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancerClin Cancer Res2006123915392116818687
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med200835936637718596266
   PubMed Web of Science ®Google Scholar
• HeCLiuMZhouCDetection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancerInt J Cancer20091252393239919530244
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• BrevetMJohnsonMLAzzoliCGLadanyiMDetection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsLung Cancer2011739610221130517
   PubMed Web of Science ®Google Scholar
• GovindanROvercoming resistance to targeted therapy for lung cancerN Engl J Med2015372181760176125923556
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular profiling of lung adenocarcinomaNature2014511751154355025079552
   PubMed Web of Science ®Google Scholar
  ErratumNature20145147521262 Rogers, K [corrected to Rodgers, K]
   Google Scholar
• HammermanPSSosMLRamosAHMutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerCancer Discov201111788922328973
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• SoriaJCFelipECoboMLUX-Lung 8 InvestigatorsAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol2015 pii: S1470-2045(15)00006-6
   Web of Science ®Google Scholar
• ArcaroATargeted therapies for small cell lung cancer: where do we stand?Crit Rev Oncol Hematol201595215416425800975
   PubMed Web of Science ®Google Scholar
• PetrioliRRovielloGLaeraLCisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experienceClin Lung Cancer2015 pii: S1525-7304(15)00137-0
   Web of Science ®Google Scholar
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Summary of RecommendationsInternational Association for the Study of Lung Cancer (IASLC)42013
   Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPBO17704 Study GroupPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAilJ Clin Oncol2009271227123419188680
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPVon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol2008263543355118506025
   PubMed Web of Science ®Google Scholar
• GainorJFVargheseAMOuSHALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerClin Cancer Res2013194273428123729361
   PubMed Web of Science ®Google Scholar
• TakahashiTSonobeMKobayashiMClinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion geneAnn Surg Oncol20101788989720183914
   PubMed Web of Science ®Google Scholar